Vincent Kuek is a passionate childhood leukaemia researcher at Telethon Kids Institute. He completed his PhD study in the area of skeletal biology at the School of Biomedical Sciences, University of Western Australia (UWA), where he investigated the role of bone-derived proteins that control healthy skeletal development and bone diseases.
Following the completion of his PhD, he continued working on industry-funded projects at UWA where he evaluated novel therapeutics in osteoporosis and osteoarthritis.
He is currently a post-doctoral research officer within the Leukaemia Translation Research laboratory at Telethon Kids Institute and a visiting collaborative researcher at the School of Biomedical Sciences, UWA. His research interests include using mouse models to understand how the environment of leukaemia cells influence disease development, and assess new treatment strategies for children with leukaemia.
ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption
Osteoporosis is a chronic skeletal condition characterized by low bone mass and deteriorated microarchitecture of bone tissue and puts tens of millions of people at high risk of fractures. New therapeutic agents like i-bodies, a class of next-generation single-domain antibodies, are needed to overcome some limitations of conventional treatments.Published research Leukaemia Translational Research
Education and Qualifications